Cargando…

Impact of prenatal substance use policies on commercially insured pregnant females with opioid use disorder

INTRODUCTION: States’ approaches to addressing prenatal substance use are widely heterogeneous, ranging from supportive policies that enhance access to substance use disorder (SUD) treatment to punitive policies that criminalize prenatal substance use. We studied the effect of these prenatal substan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabatabaeepour, Nadia, Morgan, Jake R., Jalali, Ali, Kapadia, Shashi N., Meinhofer, Angélica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357143/ https://www.ncbi.nlm.nih.gov/pubmed/35577664 http://dx.doi.org/10.1016/j.jsat.2022.108800

Ejemplares similares

Prenatal substance use policies and newborn health
por: Meinhofer, Angélica, et al.
Publicado: (2022)

Association of Criminal Statutes for Opioid Use Disorder With Prevalence and Treatment Among Pregnant Women With Commercial Insurance in the United States
por: Gressler, Laura E., et al.
Publicado: (2019)

Implementation of Group Prenatal Care for Pregnant Women on Opioid-agonist Therapy at a Community-based Substance Use Treatment Clinic
por: Zadzielski, Elizabeth, et al.
Publicado: (2018)

Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients
por: Kilaru, Austin S., et al.
Publicado: (2020)

Opioid and benzodiazepine dispensing and co-dispensing patterns among commercially insured pregnant women in the United States, 2007–2015
por: Qato, Danya M., et al.
Publicado: (2021)

Prenatal harmful substances: Thai pregnant women’s experiences
por: Tantanokit, Jatuporn, et al.
Publicado: (2023)

State Strategies to Address Opioid Use Disorder Among Pregnant and Postpartum Women and Infants Prenatally Exposed to Substances, Including Infants with Neonatal Abstinence Syndrome
por: Kroelinger, Charlan D., et al.
Publicado: (2019)

Patterns of Use of a Price Transparency Tool for Childbirth Among Pregnant Individuals With Commercial Insurance
por: Gourevitch, Rebecca A., et al.
Publicado: (2021)

Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study
por: Jeffery, Molly Moore, et al.
Publicado: (2018)

Geographic Variation in the Use of Gabapentinoids and Opioids for Pain in a Commercially Insured Adult Population in the United States
por: Zhao, Danni, et al.
Publicado: (2022)

Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use
por: Streed, Carl G., et al.
Publicado: (2022)

Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose
por: Follman, Sarah, et al.
Publicado: (2019)

Research and policy priorities for addressing prenatal exposure to opioids in Alaska
por: Singleton, Rosalyn, et al.
Publicado: (2019)

Disruption to Substance and Opioid Use Disorder: The Deep South Substance and Opioid Use Rural Training Grant
por: Allen, Rebecca, et al.
Publicado: (2021)

Cluster analysis to identify patient profiles and substance use patterns among pregnant persons with opioid use disorder
por: Charron, Elizabeth, et al.
Publicado: (2023)

Risk of Postpartum Opioid Use Disorder or Opioid Overdose After Prenatal Opioid Analgesic Use
por: Camden, Andi, et al.
Publicado: (2021)

Healthcare Resource Use and Costs Associated with Opioid Initiation Among Patients with Newly Diagnosed Endometriosis with Commercial Insurance in the USA
por: Estes, Stephanie J., et al.
Publicado: (2020)

Self-Identified Stage in Recovery and Substance-Use Behaviors among Pregnant and Postpartum Women and People with Opioid Use Disorder
por: Szlyk, Hannah S., et al.
Publicado: (2023)

Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study
por: Raman, Sudha R., et al.
Publicado: (2023)

Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression
por: Shao, Qiujun, et al.
Publicado: (2022)

Substance use identification and follow-up rates among commercial and Medicare health insurance members in primary care and other settings
por: Baker, John G., et al.
Publicado: (2020)

How the Identity of Substance Users Shapes Public Opinion on Opioid Policy
por: de Benedictis-Kessner, Justin, et al.
Publicado: (2022)

Commercial and public payer opioid analgesic prescribing policies: a case study
por: Arfken, Cynthia L., et al.
Publicado: (2021)

Setting the policy agenda for the treatment of substance use disorders in Iran
por: Mirzaei, Saeid, et al.
Publicado: (2022)

Use of Opioid-Sparing Protocols and Perceived Postpartum Pain in Patients with Opioid Use Disorder and Chronic Prenatal Opioid Exposure
por: Townsel, Courtney, et al.
Publicado: (2023)

The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability
por: Schatman, Michael E, et al.
Publicado: (2015)

Healthcare use in commercially insured youth with mental health disorders
por: Hugunin, Julie, et al.
Publicado: (2022)

Influence of Internet Use on Commercial Health Insurance of Chinese Residents
por: Xu, Bao-Chang, et al.
Publicado: (2022)

Prenatal Substance Use: Exploring Assumptions of Maternal Unfitness
por: Terplan, Mishka, et al.
Publicado: (2015)

Accuracy of Three Screening Tools for Prenatal Substance Use
por: Coleman-Cowger, Victoria H., et al.
Publicado: (2019)

Substance use in India – Policy implications
por: Singh, Om Prakash
Publicado: (2020)

Stigmatization of Pregnant Individuals with Opioid Use Disorder
por: Crawford, Allison D., et al.
Publicado: (2022)

The impact of high-risk and chronic opioid use among commercially insured endometriosis patients on health care resource utilization and costs in the United States
por: Estes, Stephanie J, et al.
Publicado: (2020)

Analysis of a Commercial Insurance Policy to Deny Coverage for Emergency Department Visits With Nonemergent Diagnoses
por: Chou, Shih-Chuan, et al.
Publicado: (2018)

Association of opioid fills with centers for disease control and prevention opioid guidelines and payer coverage policies: physician, insurance and geographic factors
por: Togun, Adeniyi T., et al.
Publicado: (2021)

Determining the Impact of Opioid Policy on Substance Use and Mental Health–Related Harms: Protocol for a Data Linkage Study
por: Xia, Ting, et al.
Publicado: (2023)

Dose patterns in commercially insured subjects chronically exposed to opioids: a large cohort study in the United States
por: Cepeda, Maria Soledad, et al.
Publicado: (2010)

The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy
por: Cheetham, Ali, et al.
Publicado: (2022)

Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
por: Cham, Stephanie, et al.
Publicado: (2022)

Nationwide Use of Telehealth Among Commercially Insured Individuals 2007–2017
por: Marcotte, Leah M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nrao2ahp31p5n474u96n6jl3ba